

ASX ANNOUNCEMENT MARKET RELEASE

19 December 2024

ISSUE OF UNQUOTED SECURITIES

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its patented artificial intelligence platform that detects key coronary artery disease imaging markers, advises that 4,282,000 unlisted securities have been issued as follows:

- 462,000 options pursuant to shareholder approval at the Company's 2024 AGM;
- 400,000 restricted stock units pursuant to the Company's Employee Incentive Plan; and
- 3,420,000 incentive performance rights pursuant to the Company's Employee Incentive Plan.

Following this announcement, Appendix 3Gs will be lodged for the above issues.

This announcement was approved by the Board.

For further information please contact:

Investor Enquiries:

Danny Younis
+61 420 293 042
danny.younis@automicgroup.com.au

Media Relations:

Rama Razy
+61 498 440 142
rama.razy@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com